Bubble Intelligence

Market Intelligence For The New Regime

AMGEN INC
AMGNamgen.com
Latest Filing: May 1, 2026 • 25 Total Filings
Total Assets
2026
$92.50B
Total Revenue
2026
$8.62B
Net Income
2026
$1.82B
Operating Cash Flow
2026
$2.19B
Filing Year:
2025
Only 2025 data available
Data Source:
Showing data from all document types
Filters:
located inlocated inlocated incompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes with
AMGEN INC
Ticker: AMGN
Unknown Region
3 suppliers
SureClick
component_supplier
⚠ Critical
TEPEZZA drug substance CMO
contract_manufacturer
⚠ Critical
KRYSTEXXA drug substance CMO
contract_manufacturer
⚠ Critical
Takeda Pharmaceutical Co., Ltd.
F. Hoffmann-La Roche Ltd.
Oncology (Vectibix vs Avastin)
Major Competitor
Eli Lilly and Company
Oncology (Vectibix vs ERBITUX)
Major Competitor
Merck KGaA
Oncology (Vectibix vs KEYTRUDA)
Major Competitor
Johnson & Johnson
Various therapeutic areas
Major Competitor
Bristol-Myers Squibb Company
Various therapeutic areas
Major Competitor
Merck & Co., Inc.
Oncology (Vectibix vs KEYTRUDA)
Major Competitor
React Flow
Legend:
Company
Critical Supplier
Significant Supplier
Standard Supplier
Major Competitor
Emerging Competitor
Competitor
Regional Supplier Concentration
0 regions with known supplier geography · 3 suppliers without location data
Risk:LowModerateElevatedHigh
3 suppliers · no geography